Literature DB >> 34330741

FDA Approves 18F-DCFPyL PET Agent in Prostate Cancer.

.   

Abstract

Entities:  

Year:  2021        PMID： 34330741

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  2 in total

1.  Prostate-specific Membrane Antigen Positron Emission Tomography, Not Conventional Imaging, Should Be Performed for Primary Staging of High-risk Prostate Cancer.

Authors:  Francesco Ceci; Gennaro Musi; Ottavio De Cobelli
Journal:  Eur Urol Open Sci       Date:  2021-10-30

2.  Head-to-Head Comparison of 68Ga-PSMA-11 PET/CT and Multiparametric MRI for Pelvic Lymph Node Staging Prior to Radical Prostatectomy in Patients With Intermediate to High-Risk Prostate Cancer: A Meta-Analysis.

Authors:  Xueju Wang; Qiang Wen; Haishan Zhang; Bin Ji
Journal:  Front Oncol       Date:  2021-10-20       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.